$188.62 Million in Sales Expected for Masimo Corporation (MASI) This Quarter
Wall Street brokerages forecast that Masimo Corporation (NASDAQ:MASI) will announce $188.62 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Masimo Corporation’s earnings. The highest sales estimate is $189.41 million and the lowest is $187.50 million. Masimo Corporation reported sales of $167.62 million in the same quarter last year, which would suggest a positive year over year growth rate of 12.5%. The firm is scheduled to report its next earnings report on Wednesday, November 1st.
On average, analysts expect that Masimo Corporation will report full year sales of $188.62 million for the current financial year, with estimates ranging from $769.00 million to $770.50 million. For the next fiscal year, analysts anticipate that the business will report sales of $824.49 million per share, with estimates ranging from $806.00 million to $838.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Masimo Corporation.
Masimo Corporation (NASDAQ:MASI) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.12. Masimo Corporation had a net margin of 45.90% and a return on equity of 23.45%. The business had revenue of $192.90 million during the quarter, compared to the consensus estimate of $189.03 million. During the same period in the previous year, the firm posted $0.57 earnings per share. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year.
A number of research firms recently commented on MASI. BidaskClub downgraded shares of Masimo Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. BTIG Research raised shares of Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research report on Monday, August 14th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $108.00 target price (up from $105.00) on shares of Masimo Corporation in a research report on Thursday, August 3rd. Zacks Investment Research raised shares of Masimo Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Masimo Corporation in a research report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Masimo Corporation presently has a consensus rating of “Hold” and a consensus price target of $95.00.
Shares of Masimo Corporation (NASDAQ:MASI) opened at 84.38 on Friday. The firm has a market capitalization of $4.38 billion, a P/E ratio of 13.83 and a beta of 0.80. The stock’s 50 day moving average is $89.41 and its 200 day moving average is $90.90. Masimo Corporation has a 1-year low of $53.78 and a 1-year high of $104.71.
ILLEGAL ACTIVITY WARNING: “$188.62 Million in Sales Expected for Masimo Corporation (MASI) This Quarter” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/01/188-62-million-in-sales-expected-for-masimo-corporation-masi-this-quarter.html.
In other news, insider Rick Fishel sold 15,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The shares were sold at an average price of $92.85, for a total value of $1,392,750.00. Following the completion of the sale, the insider now owns 35,022 shares in the company, valued at approximately $3,251,792.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anand Sampath sold 40,000 shares of the firm’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $92.00, for a total transaction of $3,680,000.00. Following the completion of the sale, the chief operating officer now owns 20,000 shares of the company’s stock, valued at approximately $1,840,000. The disclosure for this sale can be found here. In the last quarter, insiders have sold 126,000 shares of company stock valued at $11,732,930. 16.60% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. purchased a new stake in Masimo Corporation during the second quarter valued at approximately $106,000. Neuburgh Advisers LLC boosted its stake in Masimo Corporation by 6.4% in the first quarter. Neuburgh Advisers LLC now owns 1,328 shares of the medical equipment provider’s stock valued at $124,000 after buying an additional 80 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Masimo Corporation by 32.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,782 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 434 shares during the period. Glen Harbor Capital Management LLC boosted its stake in Masimo Corporation by 6.4% in the first quarter. Glen Harbor Capital Management LLC now owns 1,826 shares of the medical equipment provider’s stock valued at $170,000 after buying an additional 110 shares during the period. Finally, Dubuque Bank & Trust Co. boosted its stake in Masimo Corporation by 3.4% in the second quarter. Dubuque Bank & Trust Co. now owns 1,869 shares of the medical equipment provider’s stock valued at $170,000 after buying an additional 61 shares during the period. Institutional investors own 83.27% of the company’s stock.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related stocks with our FREE daily email newsletter.